Treating suspected community-acquired pneumonia (CAP) with a strategy of preferred empirical treatment with beta-lactam monotherapy was noninferior to strategies with beta-lactam–macrolide combination therapy or fluoroquinolone monotherapy in all-cause mortality at 90 days. Beta-lactam monotherapy was also not associated with a longer length of hospital stay or a higher incidence of complications, according to a cluster randomized crossover trial including 2283 patients admitted to non–intensive care unit wards (Postma DF et al. N Engl J Med. 2015;372:1312-1323).
Slomski A. Beta-lactam Monotherapy Noninferior for Treating Pneumonia. JAMA. 2015;313(20):2015. doi:10.1001/jama.2015.5171